Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial | Synapse
January 1, 2020Open Access
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Efficacy and Mechanism Evaluation Programme, and National Institute for Health Research and Social Care.